Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of [14C]-GDC-0810 in Healthy Females
NCT02802670Phase 1Completed
- Sponsor
- Genentech
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brilanestrant in breast cancer, sponsored by Genentech. Primary endpoints: Maximum Observed Concentration at Day 7, Time to Maximum Concentration at Day 7 and 10 more. Started May 2016; status: completed.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02802670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802670.